Generally, a gene which is inserted directly into a cell does not operate independently. Instead, the transmission of the gene is genetically modified by a biological messenger called a vector, consists of a transgene and a large DNA sequence as a backbone. Since they can deliver the new gene by infecting the cell, such viruses are also used as vectors. The adeno-associated virus (AAV) is a non-enveloped virus that can be designed to deliver DNA to target cells and has attracted considerable interest in the field, especially in experimental therapeutic strategies at the clinical level. For the new age production of COVID-19 vaccine, development of different mammalian cell lines like HEK293 (most reliable growth and prosperity for transfection) and recombinant adenoviral vectors have become the first priority for biopharmaceutical giants and globally approved vaccine manufacturers to scale up their vaccine production. Adenoviruses have a distinctive icosahedral structure, with a protein coat that encapsulates the viral double-stranded DNA genome. The adenovirus genome is relatively compact, making it an attractive option for insertion of foreign DNA. Deletion of the adenovirus E1A gene removes the virus’ ability to replicate. This ability can be restored during propagation in cell culture, for example, by using cells that express the E1A protein . Hence, in this mini review, I have shared an overview of the propagation of adenoviral vectors, i.e. recombinant adenovirus SARS CoV-2 vector in HEK-293 cell suspension culture. By evaluating human Ad5 genes (E1A, E1B19K/55K, pTP, DBP, and DNA Pol) and OCT1 for their contributions to adenovirus production, there needs to develop a rapid adenovirus production and amplification (RAPA) line .
Utkalendu Suvendusekhar Samantaray